WASHINGTON (AP) _ Abbott Laboratories said Wednesday U.S. regulators delayed a decision on its experimental cholesterol drug TriLipix, just two days after asking for more information about a another company drug. An Abbott spokesman said late Wednesday the Food and Drug Administration would need more time to complete its review of TriLipix. The agency did not ask the company for additional data on the drug and Abbott “continues to anticipate an approval in the fourth quarter of this year.” On Monday Abbott said the FDA requested more information on the controlled-release form of its painkiller Vicodin. The company had expected the drug to be approved in the fourth quarter, and it did not say if those plans have been changed.
Related Articles Read More >
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
Eicos Sciences’ FDA-approved Aurlumyn promises to drastically reduce frostbite amputations
